Bestrophin 3: A Potential Drug Target for Cancer and Neurodegenerative Disorders

Target Name: BEST3

NCBI ID: G144453

BEST3

Bestrophin 3: A Potential Drug Target for Cancer and Neurodegenerative Disorders

Bestrophin 3 (BEST3) is a protein that is expressed in various tissues throughout the body, including the heart, lungs, liver, and kidney. It is a member of the families of transmembrane protein (TMP) and tyrosine-protein kinase (TPK) proteins, which are known for their role in signaling pathways that regulate cellular processes such as cell growth, differentiation, and survival. In recent years, research has identifiedBestrophin 3 (BEST3) as a potential drug target and biomarker for various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders.

Disease-specific functions of BEST3

BEST3 is involved in several disease-specific functions that are crucial for maintaining the health and function of various tissues. One of the most well-documented functions of BEST3 is its role in cancer progression. Bestrophin 3 has been shown to promote the growth and survival of various cancer cell types, including breast, ovarian, and colorectal cancer. This is achieved through various mechanisms, such as the inhibition of cell cycle progression and the stimulation of angiogenesis (the formation of new blood vessels).

In addition to its role in cancer progression, BEST3 has also been implicated in several other diseases, including cardiovascular disease and neurodegenerative disorders. For example, research has shown that BEST3 is expressed in the brains of individuals with Alzheimer's disease and that its expression is associated with the severity of cognitive impairment. This suggests that BEST3 may be a potential drug target for Alzheimer's disease.

BEST3 as a biomarker

BEST3 has also been identified as a potential biomarker for several diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. This is achieved through the ability of BEST3 to be targeted by small molecules, such as drugs, and the ability of these molecules to interact with the protein.

One of the most promising applications of BEST3 as a biomarker is its potential to serve as a target for cancer therapies. Bestrophin 3 has been shown to promote the growth and survival of various cancer cell types, making it an attractive target for cancer therapies. example, a small molecule inhibitor of BEST3 has been shown to be effective in inhibiting the growth of breast cancer cells. Additionally, a small molecule that binds to a specific epitope on BEST3 has been shown to be effective in inhibiting the growth of ovarian cancer cells..

Another application of BEST3 as a biomarker is its potential to serve as a target for neurodegenerative disorders. Bestrophin 3 has been shown to be involved in the development and progression of several neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. Therefore, BEST3 has the potential to be a useful biomarker for these disorders.

Drug targeting of BEST3

The potential of BEST3 as a drug target has led to a significant amount of research in the field of drug development. Several small molecules have been shown to interact with BEST3 and have the potential to be used as drugs for various diseases.

One of the most promising drug targets for BEST3 is the inhibition of its activity. Small molecules that inhibit the activity of BEST3 have been shown to be effective in treating several diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. For example, a small molecule that inhibits the activity of BEST3 has been shown to be effective in inhibiting the growth of breast cancer cells. Similarly, a small molecule that inhibits the activity of B

Protein Name: Bestrophin 3

Functions: Forms calcium-sensitive chloride channels. Permeable to bicarbonate

The "BEST3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BEST3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets